⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 11, 2024VaccineOpen Access

Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland

Kwame Owusu‐Edusei Andrea Favre-Bulle Eleana Tsoumani Thomas Mutschler Nicole Cossrow

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

To assess the health and economic outcomes of a PCV13 or PCV15 age-based (65 years-and-above) vaccination program in Switzerland.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Owusu‐Edusei et al. (2024) studied this question.

synapsesocial.com/papers/68e6f858b6db643587672d99 https://doi.org/10.1016/j.vaccine.2024.04.016

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in SwitzerlandCost-Effectiveness Analysis · 2026 · 4 citations
2An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population2024 · 19 citations
3Cost effectiveness and public health impact of PCV20 among adults in FranceOriginal Research · 2026
4A cost-effectiveness analysis of 21-valent and 20-valent pneumococcal conjugate vaccines in adults aged 65 years in ItalyOriginal Research · 2026
5Economic Analysis of 15-valent and 20-valent Pneumococcal Conjugate Vaccines among Older Adults in Ontario, Canada2024 · 2 citations
6Cost-utility of pneumococcal strategies for adults aged 50 and older in Colombia: a model-based economic evaluationOriginal Research · 2026
7Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults2024 · 9 citations
8The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England2024 · 12 citations
9Timing of vaccine-associated anaphylaxis and implications for post-vaccination observation period: A systematic review and Canadian surveillance data analysisVaccine · 2026
10Changes in self-reported Long COVID in different variant-dominant phases of the SARS-CoV-2 pandemic: the influence of vaccination on a diverse Israeli cohort studyVaccine · 2026

More from Vaccine

More from Merck & Co., Inc., Rahway, NJ, USA (United States)

More from Decision Sciences (United States)

More from Athens Medical Center

More from MSD (Switzerland)